Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;5(1):35-40.
doi: 10.3892/br.2016.668. Epub 2016 Apr 28.

Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome

Affiliations

Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome

Zbyšek Pavelek et al. Biomed Rep. 2016 Jul.

Abstract

Early diagnosis and treatment of multiple sclerosis (MS) in the initial stages of the disease can significantly retard its progression. The aim of the present study was to identify changes in the cerebrospinal fluid proteome in patients with relapsing-remitting MS and clinically isolated MS syndrome who are at high risk of developing MS (case group) compared to healthy population (control) in order to identify potential new markers, which could ultimately aid in early diagnosis of MS. The protein concentrations of each of the 11 case and 15 control samples were determined using a bicinchoninic acid assay. Nanoscale liquid chromatography coupled with tandem mass spectrometry was used for protein identification. Proteomics data were processed using the Perseus software suite and R. The results were filtered using the Benjamini-Hochberg procedure for the false discovery rate (FDR) correction (FDR<0.05). The results showed that, 26 proteins were significantly dysregulated in case samples compared to the controls. Nine proteins were found to be significantly less abundant in case samples, while the abundance of 17 proteins was significantly increased in case samples compared to controls. Three of the proteins were previously linked to RR MS, including immunoglobulin (Ig) γ-1 chain C region, Ig heavy chain V-III region BRO and Ig κ chain C region. Three proteins that were uniquely expressed in patients with RR MS were identified and these proteins may serve as prognostic biomarkers for identifying patients with a high risk of developing RR MS.

Keywords: biomarkers; cerebrospinal fluid; clinically isolated syndrome; multiple sclerosis; proteins; proteomic analysis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Pearson's correlation of protein LFQ intensities between the two technical replicates of one representative sample, R=0.976.
Figure 2.
Figure 2.
Volcano plot showing significantly dysregulated proteins. The -log (P-value) is plotted against the difference of the means of the two groups (case and control). Points above the non-axial horizontal line are significantly differentially abundant proteins. Seventeen proteins were found to be significantly (P<0.002) more abundant in the case samples, while nine proteins were significantly less abundant in the case samples.
Figure 3.
Figure 3.
A boxplot graph showing differences in controls (blue bars) vs. case (red bars) for each of the dysregulated proteins. Each boxplot shows protein concentration median, interquartile ranges and the most extreme values.

References

    1. Krejsek J. News in the pathogenesis of multiple sclerosis. What is hidden behind the disability of MS patients. Remedia. 2014;2014:S2–S4. (In Czech)
    1. Cree B, Vollmer TL. Clinically isolated syndrome: Evaluation, risk stratification, and treatment decisions. Adv Stud Med. 2008;8:257–265.
    1. Garcea O, Villa A, Cáceres F, Adoni T, Alegría M, Barbosa Thomaz R, Buzo R, Llamas López L, Rivera Kindel M. Early treatment of multiple sclerosis: A Latin American experts meeting. Mult Scler. 2009;15(Suppl 3):S1–S12. doi: 10.1177/1352458509106419. - DOI - PubMed
    1. Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, Nagler B, Sibley WA, Tourtellotte WW, Willmon TL. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552–568. doi: 10.1111/j.1749-6632.1965.tb20235.x. - DOI - PubMed
    1. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983;13:227–231. doi: 10.1002/ana.410130302. - DOI - PubMed